最新糖心Vlog

An international clinical trial involving Adelaide researchers has demonstrated the safety and efficacy of a next-generation treatment for people with chronic myeloid leukaemia (CML).

The study鈥檚 lead author, Professor Tim Hughes, says successful development and testing of the new kinase inhibitor called asciminib is the biggest breakthrough in CML treatment this century.

"The development of the original tyrosine kinase inhibitor (TKI) called imatinib in the 1990s changed CML from a death sentence to a disease that in many patients could be managed until they lived to a ripe old age,鈥� Professor Hughes said.

鈥淏ut while imatinib and subsequent TKIs have been very effective at improving survival, they frequently cause serious side-effects.鈥�

TKIs that are currently approved for use are not well targeted, attacking leukaemic cells but also damaging healthy cells.

鈥淭his trial of 150 patients showed asciminib is highly effective, even in patients who鈥檇 failed to respond to several other TKIs鈥�Professor Tim Hughes

Professor Hughes is Precision Medicine theme leader with SAHMRI, Cancer Council of SA Beat Cancer Professor with the 最新糖心Vlog of Adelaide, and Consultant haematologist, Royal Adelaide Hospital.

He said asciminib selectively blocks the mutant kinase present in the leukaemic cells.

鈥淭his trial of 150 patients showed asciminib is highly effective, even in patients who鈥檇 failed to respond to several other TKIs,鈥� Professor Hughes said.

鈥淓qually as important, it鈥檚 well tolerated by patients and appears to have significantly less longterm ill-effects compared to current treatments.鈥�

The results of this clinical trial were published today in the esteemed .

CML is a blood cancer that causes bone marrow to produce too many white blood cells. This excess of mutant white blood cells interferes with normal blood cell production. TKIs slow or stop this excess production of white blood cells.

Over 4,000 最新糖心Vlogns are living with CML currently however the increasingly high survival rate brought about by TKI treatment means the disease is estimated to be the most common form of leukaemia by 2040.